Envarsus XR Approval History
FDA Approved: Yes (First approved July 10, 2015)
Brand name: Envarsus XR
Generic name: tacrolimus
Dosage form: Extended-Release Tablets
Company: Veloxis Pharmaceuticals A/S
Treatment for: Organ Transplant, Rejection Prophylaxis
Envarsus XR (tacrolimus) is a once-daily extended-release immunosuppressant for the prophylaxis of organ rejection in kidney transplant patients.
Development History and FDA Approval Process for Envarsus XR
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.